- Home
- SSBK vs FULC Comparison
SSBK vs FULC Comparison
Compare SSBK & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SSBK
- FULC
- Stock Information
- Founded
- SSBK 2007
- FULC 2015
- Country
- SSBK United States
- FULC United States
- Employees
- SSBK N/A
- FULC N/A
- Industry
- SSBK Commercial Banks
- FULC Biotechnology: Pharmaceutical Preparations
- Sector
- SSBK Finance
- FULC Health Care
- Exchange
- SSBK Nasdaq
- FULC Nasdaq
- Market Cap
- SSBK 258.6M
- FULC 221.5M
- IPO Year
- SSBK 2021
- FULC 2019
- Fundamental
- Price
- SSBK $37.11
- FULC $3.25
- Analyst Decision
- SSBK Buy
- FULC Hold
- Analyst Count
- SSBK 1
- FULC 10
- Target Price
- SSBK $36.00
- FULC $7.44
- AVG Volume (30 Days)
- SSBK 24.6K
- FULC 843.4K
- Earning Date
- SSBK 10-21-2024
- FULC 11-13-2024
- Dividend Yield
- SSBK 0.97%
- FULC N/A
- EPS Growth
- SSBK N/A
- FULC N/A
- EPS
- SSBK 3.52
- FULC N/A
- Revenue
- SSBK $87,115,000.00
- FULC $80,871,000.00
- Revenue This Year
- SSBK N/A
- FULC $2,821.96
- Revenue Next Year
- SSBK $11.75
- FULC N/A
- P/E Ratio
- SSBK $10.55
- FULC N/A
- Revenue Growth
- SSBK 1.89
- FULC 2987.86
- 52 Week Low
- SSBK $22.13
- FULC $2.86
- 52 Week High
- SSBK $37.86
- FULC $13.70
- Technical
- Relative Strength Index (RSI)
- SSBK 66.73
- FULC 44.64
- Support Level
- SSBK $35.21
- FULC $2.86
- Resistance Level
- SSBK $36.94
- FULC $3.94
- Average True Range (ATR)
- SSBK 1.36
- FULC 0.23
- MACD
- SSBK 0.08
- FULC 0.02
- Stochastic Oscillator
- SSBK 88.21
- FULC 36.11
About SSBK Southern States Bancshares Inc.
Southern States Bancshares Inc is a full-service community banking institution, that offers an array of deposit, loan, and other banking-related products and services to businesses and individuals in communities. It has three portfolio segments Real estate, Commercial and industrial, Consumer and other.
About FULC Fulcrum Therapeutics Inc.
Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company. The company's programs in clinical development are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy (FSHD) and FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and other hemoglobinopathies, including beta-thalassemia.